NCT02164955

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

A Non-interventional Post Authorisation Registry of Patients Treated With Pomalidomide for Relapsed and Refractory Multiple Myeloma Who Have Received at Least Two Prior Treatment Regimens, Including Both Lenalidomide and Bortezomib, and Have Demonstrated Disease Progression on the Last Therapy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 775 (actual)
• Sponsor: Celgene · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This registry is a prospective, multi-center, observational study and will collect safety data on multiple myeloma adult patients who have received at least two prior therapies and take IMNOVID (pomalidomide) as part of standard care. The registry will remain open until 500 patients will have received at least 3 cycles of pomalidomide. All patients registered will be followed for up to 3 years after the informed consent date or until death or withdrawal of consent. During this time the incidence of second primary malignancies (SPM), overall survival and any occurrence of a pregnancy will be assessed.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	IMNOVID	IMNOVID (pomalidomide) as prescribed in routine clinical practice

Timeline

• Start date: 2014-06-26
• Primary completion: 2022-10-10
• Completion: 2022-10-10
• First posted: 2014-06-17
• Last updated: 2022-10-20

Locations

122 sites across 8 countries: Belgium, Denmark, Germany, Italy, Norway, Spain, Sweden, United Kingdom